Login to Your Account

HGS, Novartis Bail on Zalbin After Thumbs Down from FDA

By Catherine Shaffer

Wednesday, October 6, 2010
Upon receipt of a complete response letter from the FDA, Human Genome Sciences Inc. and Novartis AG have decided not to pursue Zalbin (albinterferon alfa-2b) in hepatitis C. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription